Australia-based Propanc Biopharma, Inc. (OTC:PPCB) exploded on small-cap markets early Tuesday afternoon.
The clinical-stage biopharmaceutical company focused on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, announced it has selected LaVoieHealthScience (LHS) as its communications agency of record.
LHS is an integrated investor and public relations agency focused on advancing health and science innovations.
Propanc is developing new cancer treatments targeting high-risk patients, particularly cancer survivors, who need a follow-up, non-toxic, long-term therapy designed to prevent cancer from returning and spreading.
Its lead product, PRP, is an enhanced proenzyme formulation designed to enhance the anti-cancer effects of multiple enzymes acting synergistically. The company’s initial target patient populations include pancreatic, ovarian and colorectal cancers.
Said Propanc CEO James Nathanielsz, "As we move closer to the clinical trials stage, it’s critically important to build the right reputation amongst key stakeholders. LHS, with its proven track record in providing integrated communications to global health science innovators, will be a great long-term partner as we continue to drive PRP forward with our drug discovery efforts.”
PPCB shares sprang up a penny, or 81.7%, to 2.36 cents, on monster volume topping nine million shares.
